Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 3/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676600 | 0.92 | GRIN2B (0.61) | GRIN2BS1PR1S1PR3S1PR5SIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL1872495 | 0.87 | GRIN2B (0.55) | GRIN2BS1PR1S1PR3S1PR5SIGMAR1 | |
| SCHEMBL675978 | 0.85 | GRIN2B (0.61) | GRIN2BS1PR1S1PR3S1PR5SIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL1869763 | 0.77 | MCHR1 (0.47) | S1PR1S1PR3S1PR5 | |
| SCHEMBL21723856 | 0.77 | BAZ2B (0.52) | GRIN2B | |
| SCHEMBL21731904 | 0.72 | MEN1 (0.48) | GRIN2BHDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL949123 | 0.70 | S1PR1 (0.60) | S1PR1S1PR3S1PR5 | |
| SCHEMBL21731641 | 0.69 | MEN1 (0.50) | SIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL1869771 | 0.69 | S1PR1 (0.74) | S1PR1S1PR3SIGMAR1 | |
| SCHEMBL21731502 | 0.68 | LMNA (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371811-A2 | Azetidinecarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-05 | — | — | EP | claimed |
| US-20140023636-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-23 | — | — | US | disclosed |
| US-8575134-B2 | Aminocarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-11-05 | — | — | US | disclosed |
| EP-2371811-A2 | Azetidinecarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-05 | — | — | EP | disclosed |
| US-20110105432-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-7906549-B2 | Aminocarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090275554-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105432-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | EDNRA, EDNRB, S1PR1 | GRIN2B 939/4885S1PR1 3/4885S1PR3 15/4885 |
| US-20140023636-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | EDNRA, EDNRB, S1PR1 | GRIN2B 939/4885S1PR1 3/4885S1PR3 15/4885 |
| US-20090275554-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | EDNRA, EDNRB, S1PR1 | GRIN2B 939/4885S1PR1 3/4885S1PR3 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.